Cardiac Monitoring Needed for High-Risk Breast Cancer Patients

THURSDAY, Sept. 20, 2018 -- Risk of cardiotoxicity is higher for patients receiving trastuzumab and/or anthracyclines for the treatment of breast cancer, according to a study published in the Aug. 1 issue of JACC: Cardiovascular Imaging. Mariana L....
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news